BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $734 | -17.2% | 19,448 | 0.0% | 0.01% | -22.2% |
| Q2 2023 | $886 | +12.3% | 19,448 | 0.0% | 0.02% | +5.9% |
| Q1 2023 | $789 | -20.4% | 19,448 | 0.0% | 0.02% | -22.7% |
| Q4 2022 | $991 | -99.9% | 19,448 | 0.0% | 0.02% | -15.4% |
| Q3 2022 | $1,047,000 | -16.2% | 19,448 | 0.0% | 0.03% | -10.3% |
| Q2 2022 | $1,249,000 | -79.3% | 19,448 | -75.0% | 0.03% | -83.7% |
| Q1 2022 | $6,023,000 | -44.8% | 77,677 | -38.9% | 0.18% | -41.8% |
| Q4 2021 | $10,920,000 | +14.6% | 127,214 | +7.4% | 0.31% | -12.8% |
| Q3 2021 | $9,525,000 | +75.4% | 118,425 | +75.6% | 0.35% | +58.8% |
| Q2 2021 | $5,430,000 | -32.8% | 67,453 | -29.6% | 0.22% | -37.6% |
| Q1 2021 | $8,083,000 | +21.3% | 95,841 | +15.5% | 0.35% | +13.8% |
| Q4 2020 | $6,661,000 | +239.7% | 83,010 | +240.4% | 0.31% | +19.6% |
| Q3 2020 | $1,961,000 | +7.8% | 24,389 | +15.4% | 0.26% | -65.7% |
| Q2 2020 | $1,819,000 | +57.6% | 21,131 | +48.7% | 0.76% | +32.3% |
| Q1 2020 | $1,154,000 | -9.2% | 14,212 | -6.5% | 0.57% | +18.4% |
| Q4 2019 | $1,271,000 | – | 15,194 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |